Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
NCT07397832Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Feb 2026
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat, rituximab, polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Feb 2026; status: recruiting.
02
Drugs
tucidinostatrituximabpolatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07397832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07397832.